Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution

Magnetic resonance imaging methods allow observation of pathological changes in vivo. Magnetic resonance-based studies have provided a number of important insights into the spatio-temporal evolution of the pathology of multiple sclerosis in vivo, particularly with respect to the relation between pathology and progression of disability. Magnetic resonance techniques have shown that this pathology is not restricted to the plaques that are evident at autopsy, but also involve the so-called normal-appearing white matter. Nonconventional magnetic resonance imaging strategies such as magnetization transfer imaging and spectroscopic imaging provide measures with higher pathological specificity for myelin and axonal injury. These and other advanced magnetic resonance techniques (such as the measurement of atrophy, lesion relaxation spectra, and lesion dynamics) are affording opportunities to use observations of patients to test biologically specific hypotheses. This should help us to better define new targets for drug therapy and to assess responses to new therapeutic agents.

[1]  F. Barkhof,et al.  Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. , 1998, Journal of neurology, neurosurgery, and psychiatry.

[2]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[3]  J. Neale,et al.  Immunohistochemical localization of N-acetylaspartate in rat brain. , 1991, Neuroreport.

[4]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[5]  Guido Gerig,et al.  Exploring the discrimination power of the time domain for segmentation and characterization of active lesions in serial MR data , 2000, Medical Image Anal..

[6]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.

[7]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[8]  I. Vavasour,et al.  A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain , 2000, Neurology.

[9]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[10]  P M Matthews,et al.  Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.

[11]  P M Matthews,et al.  In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. , 1999, Brain : a journal of neurology.

[12]  G S Francis,et al.  Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. , 1999, AJNR. American journal of neuroradiology.

[13]  J. Coyle,et al.  N‐Acetyl‐Aspartyl‐Glutamate: Regional Levels in Rat Brain and the Effects of Brain Lesions as Determined by a New HPLC Method , 1984, Journal of neurochemistry.

[14]  G J Barker,et al.  Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters , 1996, Journal of magnetic resonance imaging : JMRI.

[15]  B D Trapp,et al.  Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.

[16]  N. Evangelou,et al.  Association of the APOE ε4 allele with disease activity in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.

[17]  R. Sapolsky,et al.  Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. , 1996, Stress.

[18]  A. Meyer-Franke,et al.  Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture , 1995, Neuron.

[19]  H. Adams,et al.  Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.

[20]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[21]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[22]  Bruce D. Trapp,et al.  Axonal pathology in myelin disorders , 1999, Journal of neurocytology.

[23]  Virginia M. Y. Lee,et al.  Formation of Compact Myelin Is Required for Maturation of the Axonal Cytoskeleton , 1999, The Journal of Neuroscience.

[24]  G Scarlato,et al.  Central nervous system trans‐synaptic effects of acute axonal injury: a 1h magnetic resonance spectroscopy study , 1995, Magnetic resonance in medicine.

[25]  J. Cooper,et al.  N‐ACETYL‐l‐ASPARTIC ACID CONTENT OF HUMAN NEURAL TUMOURS AND BOVINE PERIPHERAL NERVOUS TISSUES , 1972, Journal of neurochemistry.

[26]  H. Tallan,et al.  N-Acetyl-L-aspartic acid in brain. , 1956, The Journal of biological chemistry.

[27]  P. Matthews,et al.  Putting Magnetic Resonance Spectroscopy Studies in Context: Axonal Damage and Disability in Multiple Sclerosis , 1998, Seminars in neurology.

[28]  F. Condé,et al.  Early N-Acetylaspartate Depletion Is a Marker of Neuronal Dysfunction in Rats and Primates Chronically Treated with the Mitochondrial Toxin 3-Nitropropionic Acid , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  A J Thompson,et al.  Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.

[30]  G J Barker,et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.

[31]  M Rovaris,et al.  Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[32]  P M Matthews,et al.  The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis , 2000, Annals of neurology.

[33]  G. B. Pike,et al.  Relating axonal injury to functional recovery in MS , 2000, Neurology.

[34]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[35]  F. Barkhof,et al.  Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[36]  G. Barker,et al.  Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis , 1999, Neurology.

[37]  A J Thompson,et al.  Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis , 1996, Multiple sclerosis.

[38]  J. Simon From enhancing lesions to brain atrophy in relapsing MS , 1999, Journal of Neuroimmunology.

[39]  A Benazzouz,et al.  Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. , 1995, AJNR. American journal of neuroradiology.

[40]  R. Kinkel,et al.  A Wallerian degeneration pattern in patients at risk for MS , 2000, Neurology.

[41]  M. Palkovits,et al.  Axonal changes in chronic demyelinated cervical spinal cord plaques. , 2000, Brain : a journal of neurology.

[42]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[43]  T. Patel,et al.  Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. , 1979, The Biochemical journal.

[44]  Frederik Barkhof,et al.  MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) , 1999, Multiple sclerosis.

[45]  S Ropele,et al.  Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[46]  F. Barkhof,et al.  Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis , 1998, Annals of neurology.

[47]  G. Barker,et al.  Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study , 1999, Journal of Neurology.

[48]  G. Barker,et al.  Correlation of magnetization transfer ration with clinical disability in multiple sclerosis , 1994, Annals of neurology.

[49]  G. B. Pike,et al.  Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. , 2000, Radiology.

[50]  P M Matthews,et al.  Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? , 1999, Brain : a journal of neurology.

[51]  J A Frank,et al.  Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis , 1998, Annals of neurology.

[52]  M Filippi,et al.  Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T1, T2 and MT histograms , 1999, Journal of the Neurological Sciences.

[53]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[54]  D. Jeffery,et al.  Cortical deficits in multiple sclerosis on the basis of subcortical lesions , 2000, Multiple sclerosis.

[55]  O. Paulson,et al.  Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate , 2000, Multiple sclerosis.

[56]  M Noble,et al.  Specific Expression of N‐Acetylaspartate in Neurons, Oligodendrocyte‐Type‐2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro , 1992, Journal of neurochemistry.

[57]  J K Udupa,et al.  Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.

[58]  R. Kikinis,et al.  Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage , 2000, Journal of Neuroimmunology.

[59]  G J Barker,et al.  Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study , 2000, Journal of neurology, neurosurgery, and psychiatry.

[60]  G. Barker,et al.  Spinal cord atrophy and disability in MS , 1998, Neurology.

[61]  S. Kimura,et al.  Acute transient pseudoatrophy of the brain accompanying measles infection , 2000, Brain and Development.

[62]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.

[63]  K. Bhakoo,et al.  In Vitro Expression of N‐Acetyl Aspartate by Oligodendrocytes , 2000, Journal of neurochemistry.

[64]  G. Gunston,et al.  Reversible cerebral shrinkage in kwashiorkor: an MRI study. , 1992, Archives of disease in childhood.

[65]  G. Barker,et al.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.

[66]  C. Matute Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[67]  F. Barkhof,et al.  Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis. , 1999, Neurology.

[68]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[69]  G J Barker,et al.  The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. , 2000, Brain : a journal of neurology.

[70]  J. Prineas,et al.  The fine structure of chronically active multiple sclerosis plaques , 1978, Neurology.

[71]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[72]  H. Lassmann,et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.

[73]  J. Coyle,et al.  Neurochemical and Immunocytochemical Studies on the Distribution of N‐Acetyl‐Aspartylglutamate and N‐Acetyl‐Aspartate in Rat Spinal Cord and Some Peripheral Nervous Tissues , 1987, Journal of neurochemistry.

[74]  P. Matthews,et al.  Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. , 2000, Brain : a journal of neurology.

[75]  L D Blumhardt,et al.  Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.

[76]  Nikos Evangelou,et al.  Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.

[77]  M W Weiner,et al.  A serial study of new MS lesions and the white matter from which they arise , 1998, Neurology.

[78]  P M Matthews,et al.  Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. , 2000, Brain : a journal of neurology.

[79]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[80]  P M Matthews,et al.  Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.

[81]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[82]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[83]  A. Thompson,et al.  The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis , 2000 .